PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 491/22, A61K 31/439, A61P 25/00 — A1

(11) International Publication Number: **WO 00/42044**

(43) International Publication Date: 20 July 2000 (20.07.00)

(21) International Application Number: PCT/SE99/02478

(22) International Filing Date: 23 December 1999 (23.12.99)

(30) Priority Data:
9900100-0 15 January 1999 (15.01.99) SE

(71) Applicant *(for all designated States except US)*: ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: LOCH, James, III [US/US]; Astra Arcus USA, Inc., P.O. Box 20890, Rochester, NY 14603 (US). MULLEN, George [US/US]; Astra Arcus USA, Inc., P.O. Box 20890, Rochester, NY 14603 (US). PHILLIPS, Eifion [GB/US]; Astra Arcus USA, Inc., P.O. Box 20890, Rochester, NY 14603 (US).

(74) Agent: ASTRAZENECA AB; Intellectual Property, Patents, S-151 85 Södertälje (SE).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: NOVEL ARALKYL AMINES OF SPIROFUROPYRIDINES USEFUL IN THERAPY



(I)

(57) Abstract

A compound of formula (I), wherein NRR_1 is attached at the 5- or 6-position of the furopyridine ring; R is hydrogen, C_1–C_4 alkyl, or COR_2; R_1 is $(CH_2)_nAr$, $CH_2CH{=}CHAr$, or $CH_2C{\equiv}CAr$; n is 0 to 3; A is N or NO; Ar is a 5- or 6-membered aromatic or heteroaromatic ring which contains zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; or an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur, any of which may optionally be substituted with one to two substituents independently selected from: halogen, trifluoromethyl, or C_1–C_4 alkyl; R_2 is hydrogen, C_1–C_4 alkyl, C_1–C_4 alkoxy or phenyl ring optionally substituted with one to three of the following substituents: halogen, C_1–C_4 alkyl, C_2–C_4 alkenyl, C_2–C_4 alkynyl, OH; OC_1–C_4 alkyl, CO_2R_5, –CN, $–NO_2$, $–NR_3R_4$, or $–CF_3$; R_3, R_4 and R_5 may be hydrogen, C_1–C_4 alkyl, or phenyl ring optionally substituted with one to three of the following substituents: halogen, C_1–C_4 alkyl, C_2–C_4 alkenyl, C_2–C_4 alkynyl, OH; OC_1–C_4 alkyl, –CN, $–NO_2$, or $–CF_3$; and enantiomers thereof, and pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.